CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin
Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatmentCNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levelsCNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and EuropeBerubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan Drug status The…